October 6, 2009
By:Allison Tsai
Horsham, Pa. ? The U.S. Food and Drug Administration (FDA) has approved the biologic Stelara (ustekinumab, Centocor Ortho Biotech) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy, according to a Centocor press release.
 |
September 2, 2009
By:Ilya Petrou, M.D.
International report — Etanercept therapy helps to improve symptoms of depression and anxiety long-term in patients suffering from moderate-to severe psoriasis, according to the results of the Crystel study. |
September 1, 2009
By:Cheryl Guttman
Results have been analyzed from 276 patients followed for two years in the phase 3 trial of golimumab for the treatment of psoriatic arthritis. The data shows sustained benefits with no new safety signals emerging.
|
August 5, 2009
Washington — The Food and Drug Administration (FDA) says an increased risk of lymphoma and other cancers is associated with the use of drugs like Remicade (Centocor) and Humira (Abbott) in children and adolescents, the Wall Street Journal reports. |
August 1, 2009
By:Louise Gagnon
Systemic therapies, particularly anti-tumor necrosis factor (TNF) agents, are an appropriate course of therapy for patients with nail psoriasis.
|
August 1, 2009
By:Cheryl Guttman
Findings from multiple types of studies point to IL-23 as a master cytokine in the pathogenesis of psoriasis.
|
August 1, 2009
By:Cheryl Guttman
As psoriasis patients may have medical comorbidities that would have excluded them from participation in premarketing clinical trials, clinicians must turn to other sources for data to guide therapeutic decisions.
|
June 1, 2009
By:Cheryl Guttman
The investigational anti-tumor necrosis factor (TNF) monoclonal antibody golimumab (Centocor) is being evaluated as a once-a-month subcutaneous injection for the treatment of psoriatic arthritis in a Phase 3 trial that enrolled approximately 400 patients.
|
June 1, 2009
By:Cheryl Guttman
Ustekinumab (Centocor) pivotal trial data provide further evidence of the quality-of-life benefits derived when patients with moderate-to-severe psoriasis can maintain disease control.
|
| 
Practice Tools
